Sai Life Sciences Ltd.
SAILIFE · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹629.32.
Piotroski F-score 5/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%15.1%
- ✓Low debt (D/E < 0.5)0.12x
- ✕Positive free cash flow
- ✕Revenue growth > 10%4%
- ✓Earnings growing18%
- ✓Net margin ≥ 10%15.9%
- ✓Current ratio > 1.51.69
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 14.53
- ✕Piotroski ≥ 75/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (15.9%).
- •Trading near its 52-week high.
- •Financially solid — Altman Z 14.53.
Opportunities
- •Earnings growing (18% YoY).
Threats
- •Rich valuation versus sector peers.
- •Trades ~35% above our estimated fair value.
About Sai Life Sciences Ltd.
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.